Advising on intellectual property for precision medicine diagnostics Challenge A new academic spin-out company in Europe had acquired the rights to the intellectual property covering a new diagnostic agent. This molecular MRI imaging tool is envisioned to be useful in oncology indications for the early identification of certain tumors, particularly in precision medicine initiatives that target tumor-specific alterations. The burgeoning management team needed guidance on the value of the agent, the clinical path to its development, and which companies might be future licensees. Solution Numerous facets of intellectual property and business development must be considered in order to determine the optimal development path for a molecule. Our consultant first analyzed the strengths and potenti

Join for free to read